Ternary Health
Allergic & Immunologic · Alpha-Gal Syndrome

Alpha-Gal Syndrome

Up to 450,000 Americans may be affected. 78% of healthcare providers know little to nothing about this condition. You are not imagining the pattern.

About Alpha-Gal Syndrome

What we mean when we say Alpha-Gal Syndrome.

Alpha-Gal Syndrome (AGS) is an allergy to galactose-α-1,3-galactose, a sugar molecule found in mammalian meat and many medications, cosmetics, and medical products. The sensitization is typically triggered by a tick bite — most commonly the Lone Star tick in the United States. Unlike typical food allergies, reactions are often delayed by 2 to 6 hours after exposure, which makes the pattern extremely difficult to recognize without a high index of suspicion.

AGS produces a wide range of presentations, from chronic GI symptoms and unexplained urticaria to severe anaphylaxis. Reactions can be triggered by red meat, dairy, gelatin, certain medications (including some monoclonal antibodies), and even airborne exposure to cooking mammalian meat in some sensitive individuals.

Diagnosis requires specific IgE testing for alpha-gal, paired with a careful clinical history that connects symptoms to delayed exposure patterns. Most clinicians have not been trained to look for this pattern, which is why diagnostic delays are routine.

Prevalence

Up to 450,000 Americans estimated to be affected (CDC, 2023). Positive tests rose from 13,371 in 2017 to 18,885 in 2021.

The path to diagnosis

Why Alpha-Gal Syndrome gets missed.

78%
Of providers know little or nothing about AGS
CDC MMWR 2023
5%
Of providers feel confident diagnosing it
CDC MMWR 2023
2–6 hours
Typical reaction delay after exposure
AAAAI clinical guidance

Alpha-Gal Syndrome (AGS) is missed because the reaction pattern doesn't look like what most clinicians were trained to recognize as a food allergy. The delay between exposure and symptoms breaks the usual diagnostic logic, and most providers have never been taught to look for it.

  1. 01
    The 2 to 6 hour delay between mammalian exposure and reaction means patients rarely connect the trigger to the symptom. A steak at dinner becomes hives at 2 AM, and neither the patient nor the provider links the two.
  2. 02
    Standard food allergy panels do not include alpha-gal IgE. Unless specifically ordered, the test that would diagnose AGS is invisible to a routine workup.
  3. 03
    Reactions to mammalian-derived medications (gelatin capsules, certain monoclonal antibodies, heparin in some preparations) get attributed to the drug class rather than the alpha-gal content. The pattern gets fragmented across specialists.
  4. 04
    Even after diagnosis, the full scope of mammalian exposure — including cosmetics, dental materials, vaccines, and airborne cooking exposure — is rarely mapped completely. Patients continue to react and the diagnosis is doubted.
How we approach it

The Ternary Health approach to Alpha-Gal Syndrome.

01

Reconstruct the full exposure-and-reaction timeline, including tick exposure history, geographic moves, food and medication patterns, and delayed-onset symptom episodes that may not have been recognized as AGS at the time.

02

Audit the testing strategy — alpha-gal specific IgE, total tryptase, mediator workup where MCAS overlap is suspected — and identify gaps in what's been done versus what the literature recommends.

03

Map the hidden mammalian exposure landscape: medications, supplements, cosmetics, dental materials, vaccines, and personal care products. This is where ongoing symptoms most often originate after dietary changes alone.

04

Evaluate overlap with mast cell activation, hereditary alpha tryptasemia, and tick-borne co-infections — frequently coexistent and frequently the explanation for incomplete response to AGS management alone.

Signals we look for

The Ternary Signal Library for Alpha-Gal Syndrome.

Our Signal Library for Alpha-Gal Syndrome codifies the specific patterns that matter — serology, exposure context, trigger architecture, and overlap conditions. Your case is mapped against these signals; each present signal is identified and prioritized for your presentation.

Serology & Mediator Testing
  • Alpha-gal specific IgE — diagnostic and quantitative
  • Total IgE and tryptase — baseline and reaction-timed
  • Mediator panel where MCAS suspected — N-methylhistamine, prostaglandin D2
  • Co-infection serology — Lyme, Babesia, Bartonella, Ehrlichia
  • Reaction-timing protocol when mediator capture has been attempted
Trigger Map (Foods / Meds / Cosmetics)
  • Mammalian meat exposure history and tolerance pattern
  • Dairy and gelatin sensitivity — variable across patients
  • Medication audit — gelatin capsules, heparin, monoclonal antibodies, vaccines
  • Cosmetic and personal care product audit — glycerin, tallow, lanolin sources
  • Dental and surgical material exposure history
Tick Exposure & Geographic History
  • Lone Star tick exposure — confirmed bites, location, timing
  • Geographic residency pattern overlaid on AGS endemicity
  • Outdoor occupational and recreational exposure history
  • Pre- versus post-exposure symptom timeline reconstruction
  • Repeat tick exposure as IgE-level modifier
Comorbid Mast Cell & Co-Infection Patterns
  • MCAS criteria evaluation — multi-system mediator-release pattern
  • Hereditary alpha tryptasemia screening — TPSAB1 copy number
  • Tick-borne co-infection workup completeness
  • Idiopathic anaphylaxis episodes pre-dating AGS diagnosis
  • Connective tissue and dysautonomia overlap markers
The nine-stage workflow, applied

How a Alpha-Gal Syndrome case moves through our workflow.

Our nine-stage workflow is the same for every engagement. What changes per condition is the content at each stage — the records we pull, the signals we apply, the specialists we map, the pathways we evaluate. Below, how your case specifically would move through each stage.

Stage 01 · 0–2
Qualification
Fit screen confirms documented or strongly suspected AGS, access to existing serology and reaction history, and current trigger-control status. Severity history and recent reaction patterns matter for case prioritization.
Stage 02 · 3–7
Intake & data aggregation
Records pull emphasizes alpha-gal IgE results, tryptase, prior allergy workups, ER visits for reaction episodes, and current medication list. Exposure history is built as a structured timeline rather than a single intake question.
Stage 03 · 7–10
Case structuring
Case schema populated. Reaction episodes mapped against exposure types and delay intervals. MCAS criteria evaluated in parallel. Geographic and tick-exposure timeline reconstructed chronologically.
Stage 04 · 10–13
Signal analysis
The Ternary Signal Library for AGS is applied. Typical case activates 8–14 signals across serology, trigger map, exposure history, and comorbidity patterns. Each signal evaluated for your specific presentation.
Stage 05 · 13–17
Evidence retrieval
Literature scan emphasizes the AGS research consortium output: Commins, Platts-Mills, Steinke, and Wilson group publications, plus CDC MMWR surveillance data and recent reviews on hidden mammalian exposure. Condition-specific Evidence Matrix refreshed.
Stage 06 · 17–21
Pathway mapping
Pathway map built across allergy/immunology (alpha-gal specialists), GI (for delayed-reaction GI presentations), dermatology (for chronic urticaria components), and where applicable mast cell disease specialists. Specialists mapped from our Specialist Graph.
Stage 07 · 21–24
Synthesis & plan construction
Every option weighed against the three questions (Evidence × Personalization × Action), then prioritized and sequenced. Dependencies encoded as a directed graph — exposure elimination informs reaction-frequency baseline, which informs IgE retesting interval, which informs medication and procedural clearance.
Stage 08 · 24–28
Delivery & calibration
Findings call with attention to emergency action planning, hidden exposure remediation, and medication clearance protocols. Your priorities and constraints update the plan before finalization.
Stage 09 · 28–58
Execution support
30 days of asynchronous follow-up through the typical AGS consultation sequence — allergy/immunology, GI if indicated, and any pre-surgical or pre-procedure medication clearance. Outcomes captured into the Ledger.
Deliverables

What you receive.

  • A written case synthesis covering serology, reaction phenotype, and exposure architecture
  • Integration of allergy testing, trigger mapping, and mast cell workup into a single view
  • Hidden-exposure audit covering medications, cosmetics, dental materials, and personal care products
  • An emergency action plan calibrated to your reaction history and severity
  • Specialist identification for AGS-experienced allergists and any indicated comorbid workups
  • A written action plan and follow-up support as you implement it
What a Ternary report adds

What a Precision Deep Dive provides for Alpha-Gal Syndrome.

A Ternary Health Precision Deep Dive for AGS evaluates exposure history, IgE testing strategy, hidden mammalian-derived ingredients across diet and medications, cross-reactivity patterns, and management protocols including emergency planning. We also evaluate overlap with mast cell disorders, which frequently coexist and complicate the presentation.

See the published sample reports · read the Ternary Method

Frequently coexisting conditions

What we look for alongside Alpha-Gal Syndrome.

Patients with Alpha-Gal Syndrome frequently present with one or more of the following. Ternary reports evaluate the full picture rather than the condition in isolation.

Common questions — Alpha-Gal Syndrome

What prospective Alpha-Gal Syndrome clients ask most.

I tested positive for alpha-gal IgE but still react to things I shouldn't. What's going on?
This is the most common reason people apply. The usual cause is hidden mammalian exposure that hasn't been mapped — medications with gelatin or stearate, cosmetics with tallow derivatives, dental materials, or airborne cooking exposure for highly sensitive patients. The second most common cause is unrecognized mast cell activation syndrome, where alpha-gal is the trigger but the broader mast cell disorder is what's driving the symptom intensity. We map both.
Can AGS go away?
Specific IgE levels often decline over time with strict avoidance and no further tick exposure, and a subset of patients tolerate cautious reintroduction of dairy or low-alpha-gal foods after years of avoidance. The trajectory is highly individual and requires structured retesting rather than trial-and-error reintroduction at home. We build that protocol.
Do I need a formal AGS diagnosis before applying?
A positive alpha-gal IgE is preferred. If you have a clinical picture consistent with AGS but no testing yet, we can frame the workup; we do not make diagnoses, but we can map the evaluation pathway your physicians are working through.
I had a severe reaction during surgery. Can you help with surgical clearance?
Yes. Surgical and procedural clearance for AGS patients is a core part of our work — auditing anesthetic agents, surgical materials, intravenous drug carriers, and post-operative medications for mammalian-derived components. We prepare a structured clearance packet you bring to the surgical and anesthesia teams.
How does tick exposure affect ongoing management?
Repeat tick exposure can boost alpha-gal IgE and restart the clock on tolerance. Tick-bite prevention is part of every AGS plan, and post-exposure protocols matter. We build the prevention and post-exposure plan into the report.
Working through this on your own?

Three ways to engage Ternary on Alpha-Gal Syndrome.

From a free starting point to a full personalized action plan — three tiers, one methodology, all tailored to Alpha-Gal Syndrome.

Start exploring

Free Brief

$0

A 3–5 page personalized starting point on your condition. Most relevant labs, specialist categories, first decisions worth pursuing. No charge.

Generated instantly, no charge.

Get a free Brief
Get organized

Launchpad

$400

A research-based preparedness guide. Current literature, realistic prognosis, test and treatment categories worth exploring, and a checklist of what you might consider to better manage and understand your condition.

Delivered in 3–5 business days

Start a Launchpad
Get answers

Precision Deep Dive

$6,500

A vigorously researched and highly personalized action plan: the specialists and centers of excellence worth considering, evidence-graded options, and a prioritized set of questions to raise — all curated for your specific condition and lifestyle, for you and your physicians to weigh together. The plan includes 30 days of follow-up support and tailored insights into how best to navigate your situation now and in the future.

September 2026 cohort

Apply for a Deep Dive
What a Ternary report looks like

See exactly what you receive.

A composite sample illustrating the structure and depth of every Ternary Health Precision Deep Dive. Same universal 17-section format used for Alpha-Gal Syndrome — drawn from four research-validated patient profiles across four conditions.

Every Ternary engagement produces a report with the same architecture: client profile, applied methodology, signal analysis, lab and genetic findings, imaging synthesis, disease model, intervention prioritization, specialist pathway, staged medical therapy, 90-day roadmap, and monitoring cadence. The composite shows you exactly how that architecture renders.

Ready for clarity on your Alpha-Gal Syndrome?

Applications for the September 2026 cohort are open now and reviewed in the order received. Not ready? A free Ternary Brief on Alpha-Gal Syndrome is generated instantly, no charge.